RxDoctor Payments Data

Erica Wigdor, DO

Internal Medicine · Fort Lauderdale, FLNPI 1548711252

Payments from drug & device makers

$944in general payments, 2019–2025

Across 43 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$260
  • Argon Medical Devices, Inc.$147
  • Lilly USA, LLC$99
  • Pfizer$96
  • Amgen$52
  • AbbVie$47
  • plus $243 from 9 others

What the payments were for

  • Food & beverage$944100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$944 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$45,411
Medicare patients
163
Services billed
447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban13$21,192
Rosuvastatin Calcium215$2,335
Atorvastatin Calcium193$2,249
SynthroidLevothyroxine Sodium20$1,632
Losartan Potassium120$1,413
Amlodipine Besylate160$1,114
Albuterol Sulfate HfaAlbuterol Sulfate47$1,071
Nifedipine ErNifedipine32$1,035
Bupropion XlBupropion Hcl27$819
Escitalopram Oxalate56$819
Metoprolol Succinate52$747
Pantoprazole Sodium34$709
Levothyroxine Sodium102$692
Ezetimibe17$603
Omeprazole38$569

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$33$21,19213 claims
AbbVieSynthroid$47$1,63220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Fort Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →